

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Blonanserin (patches)

March 17, 2026

Therapeutic category

Psychotropic agents

Non-proprietary name

Blonanserin (patches)

Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current			Revision		
2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)			2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)		
Patients receiving the following drugs: Itraconazole, voriconazole, miconazole (oral dosage form, oral preparation, injectable dosage forms), fluconazole, fosfluconazole, posaconazole, preparations containing ritonavir, darunavir, atazanavir, fosamprenavir, ensitrelvir, preparations containing cobicistat, lonafarnib			Patients receiving the following drugs: Itraconazole, voriconazole, miconazole (oral dosage form, oral preparation, injectable dosage forms), fluconazole, fosfluconazole, posaconazole, preparations containing ritonavir, darunavir, atazanavir, fosamprenavir, ensitrelvir, preparations containing cobicistat, lonafarnib, <u>ceritinib</u>		
10. INTERACTIONS			10. INTERACTIONS		
10.1 Contraindications for Co-administration (Do not co-administer with the following.)			10.1 Contraindications for Co-administration (Do not co-administer with the following.)		
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
Drugs that strongly inhibit CYP3A4 Itraconazole Voriconazole Miconazole (oral dosage form, oral preparation, injectable dosage forms) Fluconazole Fosfluconazole Posaconazole	The blood concentration of this drug may increase, and the effects may be enhanced.	The clearance may decrease since these drugs inhibit CYP3A4, the major metabolic enzyme of this drug.	Drugs that strongly inhibit CYP3A4 Itraconazole Voriconazole Miconazole (oral dosage form, oral preparation, injectable dosage forms) Fluconazole Fosfluconazole Posaconazole	The blood concentration of this drug may increase, and the effects may be enhanced.	The clearance may decrease since these drugs inhibit CYP3A4, the major metabolic enzyme of this drug.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Preparations containing ritonavir Darunavir Atazanavir Fosamprenavir Ensitrelvir Preparations containing cobicistat Lonafarnib			Preparations containing ritonavir Darunavir Atazanavir Fosamprenavir Ensitrelvir Preparations containing cobicistat Lonafarnib <u>Ceritinib</u>		